Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Clinical Study to Evaluate KAND567 against Cardiovascular Inflammation Associated with Myocardial Infarction in Patients Suffering from Myocardial Infarction

Trial Profile

A Phase IIa Clinical Study to Evaluate KAND567 against Cardiovascular Inflammation Associated with Myocardial Infarction in Patients Suffering from Myocardial Infarction

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KAND-567 (Primary)
  • Indications Cardiovascular disorders; Inflammation; Myocardial infarction
  • Focus Therapeutic Use
  • Sponsors Kancera
  • Most Recent Events

    • 15 Jun 2020 According to a Kancera media release, company intends to apply for authorization to conduct this study in the second half of 2020.
    • 06 Mar 2020 According to an Kancera media release, this study is expected to be completed and reported within one year from the start.
    • 05 Feb 2020 According to an Kancera media release, it plans to apply to Finnish Medicines Agency for this trial in the second quarter of 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top